GlassScriptPhysician profile
John W Carter
NPI 1811919012
$9,040.04
in general payments reported to CMS, 2019-2025
26 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $855 · 2021: $1,052 · 2022: $1,722 · 2023: $1,295 · 2024: $1,703 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,282 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,282.00 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,150.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,308.74 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $951.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $815.03 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $651.23 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $541.83 | 2022-2024 | |
| Axsome Therapeutics, INC. | $515.59 | 2024-2025 | Auvelity |
| Allergan, INC. | $304.77 | 2019-2020 | |
| Astellas Pharma US INC | $256.28 | 2019-2024 | Veozah |
| Vanda Pharmaceuticals INC. | $256.11 | 2022-2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.82 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.69 | 2020-2024 | Xifaxan |
| Edwards Lifesciences Corporation | $153.01 | 2025 | Sapien 3 Ultra Resilia |
| Biohaven Pharmaceutical Holding Company LTD. | $137.57 | 2022 | |
| Amarin Pharma, INC. | $115.39 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $104.35 | 2025 | Inceptiv |
| Esperion Therapeutics, INC. | $90.52 | 2024-2025 | Nexletol |
| Exact Sciences Corporation | $73.55 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $50.80 | 2019-2021 | |
| Lundbeck LLC | $46.97 | 2023-2024 | Rexulti |
| Abbott Laboratories | $37.45 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.27 | 2019 | |
| Pfizer INC. | $25.17 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $24.02 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.08 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $15.41 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.